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Background: Ipilimumab improves survival in patients with advanced melanoma. The activity and safety of
ipilimumab outside of a clinical trial was assessed in an expanded access programme (EAP).
Methods: Ipilimumab was available upon physician request for patients aged 16 or over with pretreated stage III
(unresectable)/IV melanoma, for whom no other therapeutic option was available. Patients received ipilimumab
3 mg/kg every 3 weeks for four doses. Patients with stable disease or an objective response to ipilimumab were
eligible for retreatment upon disease progression. Tumour assessments were conducted at baseline and week 12.
Patients were monitored for adverse events (AEs) within 3 to 4 days of each scheduled visit.
Results: Of 855 patients participating in the EAP in Italy, 833 were evaluable for response. Of these, 13% had an
objective immune response, and the immune-related disease control rate was 34%. Median progression-free survival
and overall survival were 3.7 and 7.2 months, respectively. Efficacy was independent of BRAF and NRAS mutational
status. Overall, 33% of patients reported an immune-related AE (irAE). The frequency of irAEs was not associated
with response to ipilimumab.
Conclusions: Outside of a clinical trial setting, ipilimumab is a feasible treatment option in patients with pretreated
metastatic melanoma, regardless of BRAF and NRAS mutational status. Data from this large cohort of patients
support clinical trial evidence that ipilimumab can induce durable disease control and long-term survival in patients
who have failed to respond to prior treatment.
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Ipilimumab is a monoclonal antibody that blocks cyto-
toxic T-lymphocyte-associated antigen-4 (CTLA-4), a
negative regulator of T-cell activation, thereby augmen-
ting proliferation and infiltration into tumours, leading
to tumour cell death [1]. In the European Union, ipili-
mumab 3 mg/kg is indicated for adult patients with* Correspondence: paolo.ascierto@gmail.com
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unless otherwise stated.advanced (unresectable or metastatic) melanoma. In ran-
domised phase III trials, ipilimumab resulted in an over-
all survival (OS) benefit relative to control in both
pretreated and treatment-naïve patients [2,3]. Addition-
ally, long-term survival was observed with ipilimumab
alone or in combination with other agents in phase II
trials, with 5-year survival rates ranging from 13% to
36% [4-6].
Melanoma is associated with oncogenic mutations that
activate the mitogen-activated protein kinase-signalling
pathway, resulting in accelerated cell-cycle progression
and enhanced proliferation [7]. Mutations in the genes
encoding the protein kinases BRAF and NRAS are foundl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ous melanoma, respectively [8-10]. Agents approved to
treat these subpopulations include the BRAF inhibitors
vemurafenib and dabrafenib, and the MEK inhibitor
trametinib, which are indicated for adult patients
with BRAFV600 mutation-positive advanced melanoma
[11-13]. Other inhibitors of mutated MEK and/or NRAS
are in advanced clinical development [14]. However,
responses to these agents may be short-lived due to the
development of resistance and there is still a need to
explore new therapeutic options [8].
Because ipilimumab targets the tumour indirectly, its
mechanism of action is independent of kinase-signalling
pathways. A retrospective analysis of data from a phase II
trial showed that responses to ipilimumab were indepen-
dent of BRAFV600E mutation status, with 30% to 35% of all
patients achieving disease control [15]. The immune-
mediated mechanism of action results in immune-related
adverse events (irAEs), caused by increased or excessive
immune activity [16]. A relationship between irAE occur-
rence and response to ipilimumab was initially proposed
following phase II data suggesting a link with longer sur-
vival [17-19]. However, these data were inconclusive, and
disease control and survival benefits have also been ob-
served in patients not experiencing irAEs [19,20].
Here we describe the safety and efficacy of ipilimumab
3 mg/kg in patients enrolled in an expanded access
programme (EAP) in Italy. The EAP provided an oppor-
tunity to assess ipilimumab 3 mg/kg in a large cohort of
advanced melanoma patients outside of a clinical trial set-
ting (who had no other therapeutic options), with evalu-
ation of the correlation between BRAF and NRAS
mutation status and clinical benefit [21], and the potential
relationship between efficacy and irAE development [22].
Patients and methods
Patients
Details of the EAP study in Italy are also reported else-
where [23,24]. Adult patients, aged 16 or over, with
unresectable stage III/IV cutaneous, ocular or mucosal
melanoma were eligible if they had previously failed or
were intolerant to ≥1 systemic therapy, had an Eastern
Cooperative Oncology Group (ECOG) performance status
(PS) of 0 to 2, and no other therapeutic option. Previous
systemic treatment should have been completed ≥28 days
before receiving ipilimumab. Previous treatment with an
anti-CTLA-4 antibody was allowed unless prior use was
discontinued for lack of clinical benefit or an AE. Patients
with asymptomatic brain metastases at baseline were
eligible.
Study design and data collection
Patients received intravenous ipilimumab 3 mg/kg every
3 weeks for a total of four doses. In the absence of dose-limiting toxicities, patients with a stable PS received all
four doses. Dose reduction or modification was not
allowed, but dose omission or discontinuation was
recommended when necessary. Patients with disease
progression following stable disease (SD) of ≥3 months’
duration or an initial objective response (partial or
complete) were eligible for retreatment with ipilimumab
3 mg/kg every 3 weeks for four doses.
The study has been conducted in accordance with all
stipulations of the protocol and in accordance with
Good Clinical Practices, local regulatory requirements
(approved by a local Independent Ethics Committee)
and the Declaration of Helsinki.
Assessments
Tumour assessments were conducted at baseline and after
completion of treatment (week 12) according to immune-
related response criteria (irRC) [25]. Responses were
classified as immune-related complete response (irCR),
immune-related partial response (irPR), immune-related
SD (irSD) or immune-related progressive disease (irPD).
Clinical benefit was represented by immune-related best
overall response rate (irBORR; irCR or irPR) and disease
control rate (irDCR: percentage of patients achieving
irCR, irPR or irSD). BRAF and NRAS mutation status was
collected retrospectively, where possible.
AEs were monitored and assessed in all patients who
received ipilimumab and graded according to the National
Cancer Institute Common Terminology Criteria for
Adverse Events (version 3). AEs were managed using
protocol-specific guidelines. All AEs, regardless of drug at-
tribution, were recorded from the first dose of ipilimumab
until 70 days after treatment discontinuation.
Statistical analysis
Patient and disease characteristics were analysed using
descriptive statistics, and expressed as relative frequency
(percentage) for discrete variables or median for conti-
nuous variables. Progression-free survival (PFS) and OS
were estimated using Kaplan–Meier analysis and ex-
pressed as medians with corresponding two-sided 95%
confidence intervals (CIs). Differences between curves
were evaluated using the log-rank test.
Results
Patients
Between June 2010 and January 2012, 855 patients with
cutaneous (n = 631), mucosal (n = 71), and ocular (n = 83)
melanoma were treated with ipilimumab 3 mg/kg at one
of 55 Italian centres in the EAP. Baseline characteristics
are provided in Table 1. Most patients had an ECOG PS
of 0 or 1, with only 25 patients (3%) having a PS of 2. At
baseline, 17% had brain metastases and 40% had liver me-
tastases. As per protocol, all patients had received prior
Table 1 Baseline patient characteristics
Characteristic N = 855
Median age, years (range) 61 (16–88)
Male/female, n (%) 460 (54)/395 (46)
ECOG PS, n (%)
0 563 (66)
1 267 (31)
2 25 (3)
Time from diagnosis, months (range) 39 (3–280)
Tumour subtype
Cutaneous 631 (74)
Mucosal 71 (8)
Ocular 83 (10)
Primary origin unknown 70 (8)
Patients with brain metastases, n (%) 146 (17)
Patients with liver metastases, n (%) 339 (40)
Elevated LDH (≥1.10 ULN), n/n (%) 276/720 (38)
BRAF-mutation positive, n/n (%) 173/469 (37)
NRAS-mutation positive, n/n (%) 14/82 (17)
Number of previous therapies:
1 497 (58)
2 233 (27)
≥3 125 (15)
Previous therapy, n (%)
Dacarbazine 490 (57)
Fotemustine 322 (38)
Platinum-based chemotherapy 316 (37)
Paclitaxel 78 (9)
Temozolomide 189 (22)
Interferon 192 (22)
BRAF inhibitor 59 (7)
ECOG PS: Eastern Cooperative Oncology Group performance status; LDH: lactate
dehydrogenase; ULN: upper limit of normal.
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prior therapies. Although chemotherapy was the most
frequently used previous treatment, 192 patients (22%)
received prior immunotherapy with interferon and 59 pa-
tients (7%) had been treated with a BRAF inhibitor. Of
469 patients with tissue samples for retrospective testing
of the BRAF mutation, 173 (37%) were positive. Fourteen
of 82 patients (17%) tested for the NRAS mutation were
positive, including three patients who also had a BRAF
mutation.
Clinical response
With a median follow-up of 6.7 months (range, 0.5–
34 months), the irBORR was 13%, comprising 29 pa-
tients (3%) with an irCR and 82 (10%) with an irPR atany time. Twenty-two patients were not evaluable for
response for treatment refusal (n = 4), loss to follow-up
(n = 7), treatment-related toxicity (n = 3), deterioration
without progression (n = 3) or unknown reasons (n = 5).
Of 833 evaluable patients, 175 (21%) had irSD, for an
irDCR of 34%. The median duration of disease control
was 13.1 months (95% CI, 11.1–15.0). Patients with
BRAF-mutation positive tumours and BRAF wildtype
tumours had comparable irDCRs (38% vs 39%), as did
patients with or without NRAS mutations (57% vs 49%)
(Table 2).
Of 855 treated patients, 51 (6%) were retreated with ipi-
limumab 3 mg/kg upon disease progression, including 12
patients with a BRAF mutation and two with an NRAS
mutation. Of these 51 patients, the best response to induc-
tion therapy was an irCR or irPR in 20 patients and irSD
lasting ≥3 months in 31 patients. Upon retreatment, the
irDCR was 55%. Of the 12 patients with a BRAF mutation,
two had an irCR, two had an irPR and four had irSD upon
retreatment for an irDCR of 67%. Both NRAS-mutated
patients had irPD upon retreatment.
As of December 2012, median PFS among all treated
patients was 3.7 months (95% CI, 3.4–4.0; Figure 1A), and
median OS was 7.2 months (95% CI, 6.4–8.0; Figure 1B).
Survival curves were comparable between patients with
and without mutations in BRAF or NRAS (Figure 1C) and
Figure 1D). For patients with a BRAF mutation, median
OS was 11.6 months (95% CI, 9.6–13.6) versus 8.5 months
(95% CI, 7.4–9.6) for patients with wildtype BRAF. Simi-
larly, median OS for patients with an NRAS mutation was
6.7 months (95% CI, 0–20.8) versus 8.4 months (95% CI,
3.9–12.8) for patients with wildtype NRAS. One and
2-year OS rates, as of December 2012, are presented in
Figure 1.
Safety and tolerability
Among all treated patients, 399 (47%) reported an AE
(any grade), with grade 3/4 AEs in 100 patients (12%).
AEs were generally reversible with treatment as per
protocol-specific guidelines; 25 patients discontinued
ipilimumab due to toxicity. AEs leading to disconti-
nuation included diarrhoea (n = 7), rash (n = 2), liver dys-
function (n = 1), thrombocytopenia (n = 1), pain (n = 1)
and vasculitis (n = 1). Five deaths were considered to be
related to treatment (one patient each with tumour lysis
syndrome, hypothermia, bone marrow aplasia, hepatitis
and acute renal failure). For sites treating 1 to 10, 11 to
30, and over 30 patients, rates of hospitalisation for ser-
ious AEs were 9%, 5%, and 3%, respectively. The safety
profile of ipilimumab was consistent regardless of BRAF
and NRAS mutation status.
AEs were considered to be immune-related in 286 pa-
tients (33%) (Table 3), with a median time to onset of
5 weeks (range, 1–13 weeks).
Table 2 Tumour response in all patients
Patients, n (%)
Response
according to irRC
Total
(N = 833)
BRAF-mutation
positive (n = 169)
BRAF wildtype
(n = 291)
NRAS-mutation
positive (n = 14)
NRAS wildtype
(n = 67)
Any irAE
(n = 278)
No irAE
(n = 555)
irCR 29 (3) 9 (6) 12 (4) 2 (14) 4 (6) 10 (4) 19 (3)
irPR 82 (10) 19 (11) 27 (9) 2 (14) 9 (13) 31 (11) 51 (9)
irSD 175 (21) 36 (21) 76 (26) 4 (29) 20 (30) 57 (21) 118 (21)
irPD 547 (66) 105 (62) 176 (61) 6 (43) 34 (51) 180 (65) 367 (66)
irDCR 286 (34) 64 (38) 115 (39) 8 (57) 33 (49) 98 (35) 188 (34)
irRC: immune-related response criteria; irAE: immune-related adverse event; irCR: immune-related complete response; irPR: immune-related partial response;
irSD: immune-related stable disease; irPD: immune-related progressive disease; irDCR: immune-related disease control rate.
Figure 1 Kaplan–Meier curves for PFS and OS. PFS for all patients (A). OS for all patients (B). OS for BRAF-mutation positive (n = 173) and BRAF
wildtype (n = 296) patients (C). OS for NRAS-mutation positive (n = 14) and NRAS wildtype (n = 68) patients (D). OS in patients with or without an
irAE (any grade) in patients with who received three or four cycles of ipilimumab (E). PFS: progression-free survival; OS: overall survival; irAE:
immune-related adverse event.
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Table 3 Summary of irAEs
irAE Patients, n (%)
Any grade Grade 3/4
Total 286 (33) 55 (6)
Pruritus 58 (7) 1 (<1)
Rash 64 (8) 4 (<1)
Diarrhoea 60 (7) 19 (2)
Nausea 47 (6) 2 (<1)
Vomiting 15 (2) 2 (<1)
Constipation 7 (1) 1 (<1)
Abdominal pain 11 (1) 0
Endocrine 7 (1) 1 (<1)
Liver toxicity 19 (2) 15 (2)
Fatigue/asthenia 70 (8) 10 (1)
irAEs: immune-related adverse events.
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tients with or without irAEs. Most irAEs were low grade,
with grade 3/4 irAEs in 55 patients (6%; most commonly
diarrhoea, liver toxicity and fatigue/asthenia). Median
time to resolution was 1.7 weeks (range, 0.1–11.1 weeks)
for irAEs of any grade and 1.1 weeks (range, 0.1–
3.4 weeks) for grade 3/4 irAEs.
Patients who were unable to complete at least three
doses of ipilimumab (n = 194) had a lower incidence of
irAEs (22%) than those who received three or more
doses of ipilimumab (n = 661; 37% had irAEs), reflecting
the onset of some irAEs beyond initial dosing.
Relationship between efficacy and safety
The irDCRs for patients with or without an irAE of any
grade were 35% and 34%, respectively (Table 2). Among
the 278 patients with an irAE who were evaluable for
response, 10 (4%) had an irCR, 31 (11%) an irPR and
57 (21%) irSD. For these patients, median duration of
disease control was 11.7 months (95% CI, 9.9–13.5).
Respective numbers for the 555 evaluable patients with-
out an irAE were 19 (3%), 51 (9%) and 118 (21%), with a
median duration of disease control of 13.6 months
(95% CI, 11.1–6.0). After adjusting for the number of
doses completed, median OS for patients who had an
irAE was 10.1 months (95% CI, 8.9–11.3), compared
with 9.7 months (95% CI, 7.1–12.3) for those who did
not (Figure 1E).
Discussion
Ipilimumab improved survival in phase III trials of both
pretreated and treatment-naïve patients with metastatic
melanoma [2,3]. To date, over 17,000 patients have been
treated with ipilimumab, either commercially or through
clinical trials or EAPs, establishing immune-oncology as
one of the four pillars of anticancer treatment [26]. Inthe EAP, patients with no other therapeutic options,
who were ineligible for clinical trials, received ipili-
mumab at its licensed dose, providing an opportunity to
assess efficacy and safety in a large cohort of patients
outside the trial setting. Disease control and survival
data for more than 850 pretreated patients with meta-
static melanoma were consistent with clinical trial data.
In the EAP in Italy, one third of patients achieved dis-
ease control at any time according to irRC, consistent with
patients who received ipilimumab 3 mg/kg in the phase
III registrational trial which used modified World Health
Organization (WHO) criteria to evaluate bi-dimensionally
measurable lesions [2]. Encouragingly, among 51 patients
retreated with ipilimumab, 55% regained disease control,
suggesting that restimulating an immune response may be
an option for patients progressing after an initial response
to treatment [27]. Responses and/or SD with ipilimumab
can be durable, with PRs of 56 to 71+ months and CRs of
62 to 99+ months reported in phase II clinical trials [6].
Furthermore, clinical trial data consistently show a plateau
in survival curves after 2 to 3 years, with approximately
one fifth of patients having long-term survival, as
confirmed with 10 years’ follow-up for some patients
[4,5,28,29]. In preliminary landmark analyses from the
EAP, an estimated 20% of patients were still alive at least
2 years after starting ipilimumab, suggesting these patients
may also have additional life-expectancy. Extended follow-
up would be required to confirm this.
Unlike vemurafenib, which is restricted to patients with
the BRAFV600 mutation, ipilimumab can be used regard-
less of mutational status. In a previous study, DCRs were
comparable between patients with BRAFV600E-mutated
melanoma and those with wildtype tumours [15], and
EAP data support this. In the EAP, both the irDCR and
median OS appeared independent of BRAF and NRAS
status. Ipilimumab, therefore, provides clinical benefit to
patients with the BRAFV600 mutation, suggesting that
optimal sequencing of ipilimumab and vemurafenib for
BRAF-mutated metastatic melanoma should be investi-
gated further as it may be beneficial to use ipilimumab
earlier in the disease course.
Despite reproducible evidence of long-term clinical
benefit with ipilimumab, some physicians are wary of
the perceived severity and novelty of AEs resulting from
increased or excessive immune activity. In the EAP in
Italy, approximately one third of patients experienced an
irAE of any grade, which were predominantly mild. A
possible negative correlation between the number of pa-
tients treated at a site and the proportion experiencing
serious AEs was observed, and AEs tended to resolve
quicker than in clinical trials. In the registrational phase
III trial of ipilimumab, median time to resolution of
grade 3/4 immune-related AEs was 7.7 weeks (95% CI,
3.0–not reached) [2], compared with just 1.1 weeks
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gest that as physicians gain more experience of treating
patients with ipilimumab, they are more familiar with its
associated AEs, enabling earlier detection and timely
intervention. Recognition that managing AEs associated
with ipilimumab is different, but no more difficult, than
for AEs associated with non-immune agents may lead to
increased confidence in ipilimumab use.
There appeared to be no obvious differences in the
baseline characteristics of patients with and without an
irAE. Because ipilimumab can break peripheral immune
tolerance, there may be a relationship between irAEs and
response to ipilimumab [1,18]. However, in the EAP,
immune-related disease control and survival were com-
parable in patients with and without an irAE, suggesting
that patients without an irAE of any grade can still benefit
from ipilimumab as supported by previous data [19,20].
Continued vigilance and early intervention are recom-
mended to address any symptoms and prevent potentially
serious complications. Because irAEs can be severe or life-
threatening, ipilimumab should be used with caution in
patients with a history of autoimmune disease, and is con-
traindicated if the disease is active and severe.
This was an analysis of retrospective data from an
EAP that was not designed to compare efficacy out-
comes between patient subgroups, and used immune-
related rather than WHO response criteria; therefore the
results must be interpreted accordingly. Results from
Italian centres may have also been influenced by national
patient management trends. Nevertheless, the EAP pro-
vided an important opportunity to assess ipilimumab
3 mg/kg in a large cohort and a situation closely resem-
bling daily clinical practice. Ipilimumab was generally
well-tolerated, and efficacy did not appear related to
irAE occurrence. The results suggest that ipilimumab is
an effective and safe treatment for pretreated patients
with metastatic melanoma regardless of BRAF and
NRAS mutation status. Future research should focus on
assessing the longer-term, real-life outcomes of ipilimu-
mab therapy and increasing the number of patients who
benefit through improved patient selection and timely
intervention.
Consent
All participating patients provided signed informed con-
sent for administration of the drug, academic evaluation
of clinical outcomes and publications or reports related
to the compassionate use programme before enrolment.
For patients below the legal age, consent from parents,
guardians, or next of kin has been provided.
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